Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cassava Sciences Inc (SAVA) USD0.001

Sell:$3.10 Buy:$3.28 Change: $0.005 (0.16%)
NASDAQ:1.44%
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Sell:$3.10
Buy:$3.28
Change: $0.005 (0.16%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
Sell:$3.10
Buy:$3.28
Change: $0.005 (0.16%)
Market closed |  Prices as at close on 8 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Contact details

Address:
7801 N Capital of Texas Hwy Ste 260
AUSTIN
78731-1192
United States
Telephone:
+1 (512) 5012444
Website:
https://www.cassavasciences.com/company

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SAVA
ISIN:
US14817C1071
Market cap:
$77.31 million
Shares in issue:
24.78 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Remi Barbier
    Chairman of the Board, President, Chief Executive Officer
  • Eric Schoen
    Chief Financial Officer
  • Nadav Friedmann
    Chief Medical and Operating Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.